WT1 and neoplasm: When incorporated into two TCR-like CARs, (HLA)-A2/GPC3- and HLA-A2/WT1-specific nanobodies selectively recognize and lyse MHC/peptide complex-expressing tumor cells both in vivo and in vitro.